ALLUVI: A DETAILED EXAMINATION INTO RETATRUTIDE'S POTENTIAL

Alluvi, formerly BI 4744, offers a significant breakthrough in weight loss treatment. This dual stimulator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling results in clinical studies, arguably outperforming current GLP-1 target